Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DGN26L
|
|||
| Drug Name |
BST-236
|
|||
| Synonyms |
Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 2 | [1] | |
| Company |
BioSight
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H18N4O8
|
|||
| Canonical SMILES |
C1=CN(C(=O)N=C1NC(=O)CC(C(=O)O)N)C2C(C(C(O2)CO)O)O
|
|||
| InChI |
1S/C13H18N4O8/c14-5(12(22)23)3-8(19)15-7-1-2-17(13(24)16-7)11-10(21)9(20)6(4-18)25-11/h1-2,5-6,9-11,18,20-21H,3-4,14H2,(H,22,23)(H,15,16,19,24)/t5-,6+,9+,10-,11+/m0/s1
|
|||
| InChIKey |
PVPJTBAEAQVTPN-HRAQMCAYSA-N
|
|||
| CAS Number |
CAS 2098942-53-9
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04827719) BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.